OncoGenex Pharmaceuticals CEO Richard Stewart's 2019 pay falls 27% to $797K
OncoGenex Pharmaceuticals reports 2019 executive compensation
By ExecPay News
Published: April 2, 2020
OncoGenex Pharmaceuticals reported fiscal year 2019 executive compensation information on April 2, 2020.
In 2019, four executives at OncoGenex Pharmaceuticals received on average a compensation package of $634K, a 21% decrease compared to previous year.
Average pay of disclosed executives at OncoGenex Pharmaceuticals
Richard Stewart, Chief Executive Officer, received $797K in total, which decreased by 27% compared to 2018. 63% of Stewart's compensation, or $500K, was in salary. Stewart also received $188K in non-equity incentive plan and $109K in option awards.
Anthony Clarke, Chief Scientific Officer, received a compensation package of $590K, which decreased by 18% compared to previous year. 71% of the compensation package, or $420K, was in salary.
Cindy Jacobs, Chief Medical Officer, earned $581K in 2019, a 18% decrease compared to previous year.
John Bencich, Chief Financial Officer, received $571K in 2019, which decreases by 18% compared to 2018.
Related executives
You may also like
Source: SEC filing on April 2, 2020.